GLOBEIMMUNE INC (OTCMKTS:GBIM) Shorted Shares Increased 10.71% After Market Selling

April 6, 2018 - By Vivian Park

GlobeImmune, Inc. (OTCMKTS:GBIM) Logo

The stock of GLOBEIMMUNE INC (OTCMKTS:GBIM) registered an increase of 10.71% in short interest. GBIM’s total short interest was 9,300 shares in April as published by FINRA. Its up 10.71% from 8,400 shares, reported previously. With 7,500 shares average volume, it will take short sellers 1 days to cover their GBIM’s short positions.

It closed at $0.57 lastly. It is down 0.00% since April 6, 2017 and is . It has underperformed by 11.55% the S&P500.

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. The company has market cap of $3.28 million. The Company’s product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. It currently has negative earnings. The firm is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.